Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference

May 29, 2024

MORRISVILLE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Michael Kaseta, chief operating officer and chief financial officer, will provide an update on the company's business during a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday June 5, 2024, beginning at 9:00 a.m. ET, in New York City, NY.

Access to a webcast will be available to investors and other interested parties by accessing Liquidia’s website at

An archived, recorded version of the presentation will be available on Liquidia’s website for at least 30 days following the event.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of PAH and PH-ILD. Liquidia Technologies is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a next-generation nebulizer, for use in North America. Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit

Contact Information

Jason Adair
Chief Business Officer

Patrick Wallace
Director, Corporate Communications

Primary Logo

Source: Liquidia Corporation